Michael Hogarty Laboratory
A Phase I clinical study is underway to evaluate the safety and possible effectiveness of a combination of DFMO and celecoxib plus cyclophosphamide and topotecan as a treatment for children with relapsed neuroblastoma.
CHD5, a gene located on the distal portion of the short arm of chromosome 1, may function as a tumor suppressor gene and contribute to the development of malignant neuroblastoma when deleted.
Researchers at the Center for Childhood Cancer Research (CCCR) have revealed that iNKT cells not only directly kill certain tumors, but also secrete cytokines that indirectly promote the tumoricidal activity of other cytotoxic lymphocytes such as CD8+ T-cells and NK cells.
Researchers at the Center for Childhood Cancer Research are using preclinical tumor cell-based assays and mouse models to evaluate drugs that interfere with polyamine synthesis and assess their effects on cancer cell growth and immune function in the tumor microenvironment.
Researchers at the Center for Childhood Cancer Research are working to generate a series of position papers intended to detail the recommended best practices for pediatric cancer surveillance.
Studies are underway to identify the molecular mechanisms that give rise to therapy-resistant pediatric neuroblastoma.
Researchers at the Center for Childhood Cancer Research (CCCR) are studying how modulation of T-cell receptor signaling may alter T-cell exhaustion.
Researchers used a combination of next generation sequencing strategies to identify mutations in two related cancer genes that had not previously been linked to childhood neuroblastomas.
Inhibition of the TRK tyrosine kinase family has shown enduring response in clinical trials and efforts are underway to assess newer TRK inhibitors.
Researchers are currently enrolling patients for this Phase III trial assessing the addition of the radiopharmaceutical MIBG to standard care for high-risk neuroblastoma.